Biomarker & Intervention Discovery

Hepatitis C

This page lists 15 druggable gene targets, 54 approved or trial-tested drug candidates and 15 recent clinical trials for Hepatitis C, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Plain-language summary → New Treatments for Hepatitis C (2026): Drugs in Trials

US DALYs146.1KWHO GHE 2021 · all ages
Global DALYs4.70MWHO GHE 2021 · worldwide
US mortality4,555 deaths/yrWHO GHE 2021
Global mortality88.1K deaths/yrWHO GHE 2021 · worldwide
NIH funding$86MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionSpontaneous clearance in <30% of acute cases; chronic infection rarely clears without treatment (<1%/year)
Best-intervention remission>95% cured (sustained virologic response at 12 weeks) with 8-12 week courses of direct-acting antivirals (DAAs)
Gap sizeNear-zero biological gap; large access/utilization gap
Primary barrieraccess
Full remission profile →
Research Tracker Chronic Disease Interventions Hepatitis C Biomarker Atlas →

Remission & chronicity

Spontaneous remission
Spontaneous clearance in <30% of acute cases; chronic infection rarely clears without treatment (<1%/year)
Best-intervention remission
>95% cured (sustained virologic response at 12 weeks) with 8-12 week courses of direct-acting antivirals (DAAs)
Gap size
Near-zero biological gap; large access/utilization gap
Primary barrier
access
Only 65% of eligible patients with private insurance received DAA treatment as of 2020; rates declining since 2019; Medicaid restrictions remain in many states; $20,000+ drug cost for generics unavailable in US

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

DDX58 1HAVCR2 78IFIT1 2IFNAR1 19IFNL3 25IFNL4 15IRF3 2IRF9 0MAVS 2MX1 0OAS1 3PDCD1 44STAT1 6TGFB1 62TLR3 18

DDX58

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INARIGIVIR SOPROXIL ? unclear Mechanistic DGIdb

HAVCR2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SABATOLIMAB ↓ inhibits Mechanistic DGIdb
ANTI-TIM-3 MONOCLONAL ANTIBODY ? unclear Mechanistic DGIdb
PD1 INHIBITOR ? unclear Mechanistic DGIdb
ANTI-TIM3 MONOCLONAL ANTIBODY LY3321367 ? unclear Mechanistic DGIdb
LOMVASTOMIG ↓ inhibits Mechanistic DGIdb
COBOLIMAB ↓ inhibits Mechanistic DGIdb
CHEMBL1569082 ↓ inhibits Mechanistic 810000.0 nM (Kd) ChEMBL
CHEMBL4876694 ↓ inhibits Mechanistic 330000.0 nM (Kd) ChEMBL
CHEMBL4866110 ↓ inhibits Mechanistic 250000.0 nM (Kd) ChEMBL
CHEMBL4860123 ↓ inhibits Mechanistic 40000.0 nM (Kd) ChEMBL
CHEMBL4870128 ↓ inhibits Mechanistic 40000.0 nM (Kd) ChEMBL
CHEMBL4852144 ↓ inhibits Mechanistic 50000.0 nM (Kd) ChEMBL
CHEMBL4864057 ↓ inhibits Mechanistic 90000.0 nM (Kd) ChEMBL
CHEMBL4871549 ↓ inhibits Mechanistic 90000.0 nM (Kd) ChEMBL
CHEMBL4870200 ↓ inhibits Mechanistic 40000.0 nM (Kd) ChEMBL
CHEMBL4854696 ↓ inhibits Mechanistic 40000.0 nM (Kd) ChEMBL
CHEMBL4863477 ↓ inhibits Mechanistic 10000.0 nM (Kd) ChEMBL
CHEMBL4865760 ↓ inhibits Mechanistic 130000.0 nM (Kd) ChEMBL
CHEMBL4876887 ↓ inhibits Mechanistic 450000.0 nM (Kd) ChEMBL
CHEMBL1610810 ↓ inhibits Mechanistic 460000.0 nM (Kd) ChEMBL
CHEMBL1462057 ↓ inhibits Mechanistic 530000.0 nM (Kd) ChEMBL
CHEMBL4854485 ↓ inhibits Mechanistic 740000.0 nM (Kd) ChEMBL
CHEMBL69086 ↓ inhibits Mechanistic 670000.0 nM (Kd) ChEMBL
CHEMBL4864031 ↓ inhibits Mechanistic 780000.0 nM (Kd) ChEMBL
CHEMBL2132792 ↓ inhibits Mechanistic 1400000.0 nM (Kd) ChEMBL
CHEMBL1576751 ↓ inhibits Mechanistic 850000.0 nM (Kd) ChEMBL
CHEMBL4848599 ↓ inhibits Mechanistic 2000.0 nM (Kd) ChEMBL
CHEMBL4873902 ↓ inhibits Mechanistic 250.0 nM (Kd) ChEMBL
CHEMBL4859588 ↓ inhibits Mechanistic 1600.0 nM (Ki) ChEMBL
CHEMBL4860976 ↓ inhibits Mechanistic 2100.0 nM (Ki) ChEMBL
CHEMBL4874818 ↓ inhibits Mechanistic 1500.0 nM (Ki) ChEMBL
CHEMBL4851756 ↓ inhibits Mechanistic 1800.0 nM (Ki) ChEMBL
CHEMBL4872496 ↓ inhibits Mechanistic 2200.0 nM (Ki) ChEMBL
CHEMBL4876721 ↓ inhibits Mechanistic 2300.0 nM (Ki) ChEMBL
CHEMBL4864303 ↓ inhibits Mechanistic 2600.0 nM (Ki) ChEMBL
CHEMBL4846039 ↓ inhibits Mechanistic 1500.0 nM (Ki) ChEMBL
CHEMBL4875904 ↓ inhibits Mechanistic 1300.0 nM (Ki) ChEMBL
CHEMBL4868118 ↓ inhibits Mechanistic 970.0 nM (Ki) ChEMBL
CHEMBL4873816 ↓ inhibits Mechanistic 550.0 nM (Ki) ChEMBL
CHEMBL4863017 ↓ inhibits Mechanistic 750.0 nM (Ki) ChEMBL

Showing top 40 of 78 agents ranked by evidence tier.

IFIT1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PEGINTERFERON ALFA-2B ? unclear Mechanistic DGIdb
RIBAVIRIN ? unclear Mechanistic DGIdb

IFNAR1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INTERFERON ALFACON-1 ↑ activates Mechanistic DGIdb
INTERFERON BETA ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ↑ activates Mechanistic DGIdb
INTERFERON BETA-1B ↑ activates Mechanistic DGIdb
PEGINTERFERON BETA-1A ↑ activates Mechanistic DGIdb
ALBINTERFERON ALFA-2B ↑ activates Mechanistic DGIdb
ROPEGINTERFERON ALFA-2B ~ modulates Mechanistic DGIdb
INTERFERON ALFA ? unclear Mechanistic DGIdb
INTERFERON ALFA-2B ↑ activates Mechanistic DGIdb
GLATIRAMER ? unclear Mechanistic DGIdb
INTERFERON ALFA-N1 ? unclear Mechanistic DGIdb
INTERFERON BETA-1A ↑ activates Mechanistic DGIdb
PEGINTERFERON ALFACON-1 ? unclear Mechanistic DGIdb
ANIFROLUMAB ↓ inhibits Mechanistic DGIdb
PEGINTERFERON ALFA-2B ↑ activates Mechanistic DGIdb
INTERFERON ALFA-N3 ↑ activates Mechanistic DGIdb
SIFALIMUMAB ? unclear Mechanistic DGIdb
INTERFERON ALFA-2A ? unclear Mechanistic Open Targets
CHEMBL1617534 ↓ inhibits Mechanistic 4000.0 nM (Kd) ChEMBL

IFNL3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ASUNAPREVIR ? unclear Mechanistic DGIdb
VOXILAPREVIR ? unclear Mechanistic DGIdb
PARITAPREVIR ? unclear Mechanistic DGIdb
SIMEPREVIR ? unclear Mechanistic DGIdb
OMBITASVIR ? unclear Mechanistic DGIdb
INTERFERON ALFA-N1 ? unclear Mechanistic DGIdb
ELBASVIR/GRAZOPREVIR ? unclear Mechanistic DGIdb
SOFOSBUVIR ? unclear Mechanistic DGIdb
LEDIPASVIR ? unclear Mechanistic DGIdb
DELEOBUVIR ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2B ? unclear Mechanistic DGIdb
DASABUVIR ? unclear Mechanistic DGIdb
DACLATASVIR ? unclear Mechanistic DGIdb
ELBASVIR ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ? unclear Mechanistic DGIdb
RITONAVIR ? unclear Mechanistic DGIdb
SOFOSBUVIR / VELPATASVIR / VOXILAPREVIR ? unclear Mechanistic DGIdb
GRAZOPREVIR ? unclear Mechanistic DGIdb
FALDAPREVIR ? unclear Mechanistic DGIdb
VELPATASVIR ? unclear Mechanistic DGIdb
TELAPREVIR ? unclear Mechanistic DGIdb
OMBITASVIR/PARITAPREVIR/RITONAVIR ? unclear Mechanistic DGIdb
SOFOSBUVIR/VELPATASVIR ? unclear Mechanistic DGIdb
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic DGIdb
BOCEPREVIR ? unclear Mechanistic DGIdb

IFNL4

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
LEDIPASVIR ? unclear Mechanistic DGIdb
INTERFERON ALFA-N1 ? unclear Mechanistic DGIdb
FALDAPREVIR ? unclear Mechanistic DGIdb
VELPATASVIR ? unclear Mechanistic DGIdb
DELEOBUVIR ? unclear Mechanistic DGIdb
INTERFERON ALFA-2B ? unclear Mechanistic DGIdb
OMBITASVIR/PARITAPREVIR/RITONAVIR ? unclear Mechanistic DGIdb
ASUNAPREVIR ? unclear Mechanistic DGIdb
BOCEPREVIR ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ? unclear Mechanistic DGIdb
DACLATASVIR ? unclear Mechanistic DGIdb
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic DGIdb
SIMEPREVIR ? unclear Mechanistic DGIdb
VOXILAPREVIR ? unclear Mechanistic DGIdb
ELBASVIR/GRAZOPREVIR ? unclear Mechanistic DGIdb

IRF3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RECOMBINANT INTERFERON ? unclear Mechanistic DGIdb
CHEMBL4471585 ↑ activates Mechanistic 27600.0 nM (EC50) ChEMBL

IRF9

UniProt Ensembl DGIdb Open Targets

Pipeline results not yet available for this target. Run the pipeline to populate.

MAVS

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CHEMBL5653589 ↓ inhibits Mechanistic 392.68 nM (Kd) ChEMBL
CHEMBL3752910 ↓ inhibits Mechanistic 5243.38 nM (Kd) ChEMBL

MX1

UniProt Ensembl DGIdb Open Targets

Pipeline results not yet available for this target. Run the pipeline to populate.

OAS1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RIBAVIRIN ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2B ? unclear Mechanistic DGIdb

PDCD1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PEMBROLIZUMAB ↓ inhibits Mechanistic DGIdb
PUCOTENLIMAB ↓ inhibits Mechanistic DGIdb
TISLELIZUMAB ↓ inhibits Mechanistic DGIdb
EZABENLIMAB ? unclear Mechanistic DGIdb
ANTI-PD-1 MONOCLONAL ANTIBODY SYM021 ? unclear Mechanistic DGIdb
AMP-224 ? unclear Mechanistic DGIdb
SPARTALIZUMAB ↓ inhibits Mechanistic DGIdb
DOSTARLIMAB ↓ inhibits Mechanistic DGIdb
CEMIPLIMAB ↓ inhibits Mechanistic DGIdb
CT-011 ? unclear Mechanistic DGIdb
LOMVASTOMIG ↓ inhibits Mechanistic DGIdb
PIDILIZUMAB ↓ inhibits Mechanistic DGIdb
CADONILIMAB ↓ inhibits Mechanistic DGIdb
CAMRELIZUMAB ↓ inhibits Mechanistic DGIdb
PENPULIMAB ↓ inhibits Mechanistic DGIdb
MEDI0680 ? unclear Mechanistic DGIdb
FINOTONLIMAB ↓ inhibits Mechanistic DGIdb
CETRELIMAB ↓ inhibits Mechanistic DGIdb
SERPLULIMAB ↓ inhibits Mechanistic DGIdb
BUDIGALIMAB ↓ inhibits Mechanistic DGIdb
LIPUSTOBART ? unclear Mechanistic DGIdb
DURVALUMAB ? unclear Mechanistic DGIdb
BALSTILIMAB ↓ inhibits Mechanistic DGIdb
RETIFANLIMAB ↓ inhibits Mechanistic DGIdb
TEBOTELIMAB ↓ inhibits Mechanistic DGIdb
BINTRAFUSP ALFA ? unclear Mechanistic DGIdb
APL-501 ↓ inhibits Mechanistic DGIdb
VUDALIMAB ? unclear Mechanistic DGIdb
AUNP-12 ? unclear Mechanistic DGIdb
CS-1003 ↓ inhibits Mechanistic DGIdb
ZIMBERELIMAB ↓ inhibits Mechanistic DGIdb
PIMIVALIMAB ↓ inhibits Mechanistic DGIdb
SINTILIMAB ↓ inhibits Mechanistic DGIdb
CC-90006 ? unclear Mechanistic DGIdb
GEPTANOLIMAB ? unclear Mechanistic DGIdb
TORIPALIMAB ↓ inhibits Mechanistic DGIdb
NIVOLUMAB ↓ inhibits Mechanistic DGIdb
SASANLIMAB ↓ inhibits Mechanistic DGIdb
CHEMBL4436009 ↓ inhibits Mechanistic 3390.0 nM (Kd) ChEMBL
CHEMBL4458745 ↓ inhibits Mechanistic 3140.0 nM (Kd) ChEMBL

Showing top 40 of 44 agents ranked by evidence tier.

STAT1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CISPLATIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL85826 ? unclear Mechanistic DGIdb
PICOPLATIN ? unclear Mechanistic DGIdb
GUTTIFERONE K ? unclear Mechanistic DGIdb
IPRIFLAVONE ? unclear Mechanistic DGIdb
GARCINOL ? unclear Mechanistic DGIdb

TGFB1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
INTERFERON ALFA-2B ? unclear Mechanistic DGIdb
PIOGLITAZONE HYDROCHLORIDE ? unclear Mechanistic DGIdb
SILYMARIN ? unclear Mechanistic DGIdb
RITUXIMAB ? unclear Mechanistic DGIdb
VERAPAMIL ? unclear Mechanistic DGIdb
PROTEASOME INHIBITOR ? unclear Mechanistic DGIdb
FRESOLIMUMAB ? unclear Mechanistic DGIdb
ATENOLOL ? unclear Mechanistic DGIdb
BINTRAFUSP ALFA ~ modulates Mechanistic DGIdb
NISEVOKITUG ? unclear Mechanistic DGIdb
LUSPATERCEPT ↓ inhibits Mechanistic DGIdb
TRETINOIN ? unclear Mechanistic DGIdb
HYDROCORTISONE BUTYRATE ? unclear Mechanistic DGIdb
VITAMIN E ? unclear Mechanistic DGIdb
IRINOTECAN HYDROCHLORIDE ? unclear Mechanistic DGIdb
INOSITOL ? unclear Mechanistic DGIdb
NICOTINE POLACRILEX ? unclear Mechanistic DGIdb
FENRETINIDE ? unclear Mechanistic DGIdb
MELATONIN ? unclear Mechanistic DGIdb
ISOTRETINOIN ? unclear Mechanistic DGIdb
VACTOSERTIB ? unclear Mechanistic 12.9 nM (IC50) DGIdb
TRIAMCINOLONE ? unclear Mechanistic DGIdb
TAMOXIFEN ? unclear Mechanistic DGIdb
ADRIAMYCIN ? unclear Mechanistic DGIdb
HEPARAN SULFATE ? unclear Mechanistic DGIdb
GOSSYPOL ? unclear Mechanistic DGIdb
TCDD ? unclear Mechanistic DGIdb
AMIFOSTINE ANHYDROUS ? unclear Mechanistic DGIdb
RAMIPRIL ? unclear Mechanistic DGIdb
ANTIOXIDANT ? unclear Mechanistic DGIdb
SOTATERCEPT ? unclear Mechanistic DGIdb
ASPIRIN ? unclear Mechanistic DGIdb
GALUNISERTIB ? unclear Mechanistic DGIdb
KEYHOLE LIMPET HEMOCYANIN ? unclear Mechanistic DGIdb
PIRFENIDONE ? unclear Mechanistic DGIdb
H2O2 ? unclear Mechanistic DGIdb
THERAPEUTIC ANDROGEN ? unclear Mechanistic DGIdb
SANDOSTATIN ? unclear Mechanistic DGIdb
BROXURIDINE ? unclear Mechanistic DGIdb
DISITERTIDE ? unclear Mechanistic DGIdb

Showing top 40 of 62 agents ranked by evidence tier.

TLR3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
POLY ICLC ? unclear Mechanistic DGIdb
POLY(I:C) ↑ activates Mechanistic DGIdb
BEVASIRANIB ↑ activates Mechanistic DGIdb
ASPIRIN ? unclear Mechanistic DGIdb
RINTATOLIMOD ↑ activates Mechanistic DGIdb
IL-4 ? unclear Mechanistic DGIdb
IL-13 ? unclear Mechanistic DGIdb
MEASLES VACCINE ? unclear Mechanistic DGIdb
BEVASIRANIB SODIUM ↑ activates Mechanistic DGIdb
HYDROXYCHLOROQUINE ? unclear Mechanistic DGIdb
CHEMBL4064228 ↑ activates Mechanistic 42500.0 nM (EC50) ChEMBL
CHEMBL4074408 ↑ activates Mechanistic 4800.0 nM (EC50) ChEMBL
CHEMBL4105063 ↑ activates Mechanistic 22300.0 nM (EC50) ChEMBL
CHEMBL4636498 ↓ inhibits Mechanistic 5440.0 nM (IC50) ChEMBL
CHEMBL4647818 ↓ inhibits Mechanistic 2160.0 nM (IC50) ChEMBL
CHEMBL4795714 ↓ inhibits Mechanistic 2400.0 nM (IC50) ChEMBL
CHEMBL19954 ↓ inhibits Mechanistic 110.0 nM (IC50) ChEMBL
CHEMBL4303728 ↓ inhibits Mechanistic 3440.0 nM (IC50) ChEMBL

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Hepatitis C: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

The Kentucky Viral Hepatitis Treatment Study Completed
NCT03949764 Phase: 4 Started: 2019-09-23

The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to ...

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Active Not Recruiting
NCT05140941 Phase: 4 Started: 2022-04-04

This is a multicenter, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy. Treatment will be initiated during the second or third trimester in approximately 100 pregnant people. Maternal participants will take one SOF/VEL tablet once ...

Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania Recruiting
NCT06159504 Phase: Early 1 Started: 2024-10-03

The goal of this non-randomised, quasi-experimental, prospective comparative trial is to trial simplified care pathways for hepatitis C testing and treatment for people who inject drugs in Armenia, Georgia, and Tanzania. The main questions it aims to answer are: 1. What is the feasibility of impleme...

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV Recruiting
NCT07040319 Phase: 1/2 Started: 2026-06-25

This is a Phase I/II, multi-site, open-label, single arm study to describe the pharmacokinetics (PK) and safety of glecaprevir/pibrentasvir (GLE/PIB) initiated during pregnancy in women with hepatitis C virus (HCV) infection (acute or chronic) with or without HIV and to evaluate safety for their inf...

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir Recruiting
NCT03855917 Phase: 4 Started: 2020-02-11

This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver ...

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Active Not Recruiting
NCT07037277 Phase: 3 Started: 2025-06-02

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir Completed
NCT02647632 Phase: 2 Started: 2016-01

The primary objective of this study is to estimate, in HCV genotype 1 or 4-infected patients who failed a prior DAA bitherapy with Sofosbuvir, the efficacy of a treatment with Grazoprevir/Elbasvir, Sofosbuvir and Ribavirin in the two treatment groups and compare the rate of sustained virological res...

Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC Completed
NCT02771405 Phase: 3 Started: 2016-03

The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.

Implementing Low-Barrier HCV Treatment in a Jail Setting Recruiting
NCT06953479 Phase: 4 Started: 2025-06-11

The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting t...

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients Active Not Recruiting
NCT04508907 Phase: 4 Started: 2020-09-10

This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV Active Not Recruiting
NCT06868264 Phase: 3 Started: 2025-04-07

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Completed
NCT05904470 Phase: 2 Started: 2023-05-30

This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study Completed
NCT03987503 Phase: 4 Started: 2020-07-01

Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) offers a cure to those with chronic HCV infection. For marginalized communities, linkage to care services often aren't enough to overcome barriers to accessing the medical system. For difficult to link populations, offering treatment ...

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) Completed
NCT04903626 Phase: 3 Started: 2021-08-24

HCV infection is a global health problem. HCV mainly affects liver cells and causes the liver to become inflamed and damaged. This study will evaluate how safe and effective glecaprevir/pibrentasvir (GLE/PIB) is in adult and adolescent participants with acute HCV infection. GLE/PIB is an approved dr...

8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Completed
NCT04885855 Phase: 2/3 Started: 2021-03-23

This is open-label, randomized, multicentre study to compare the efficacy and safety of the 8-week versus 12-week of SOF-RVD combination treatment for non-cirrhotic chronic hepatitis C patients. All the recruited subjects will receive the treatment accordingly and be followed up for 24 weeks followi...

Agents Found By Disease-Level Search

Searched directly from “Hepatitis C” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 15-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

54 agents shown (approved or with trial evidence) — 50 not found by the gene-target search above.

Ribavirin

· 8 trials · source: ClinicalTrials.gov
NCT01833533 NCT02786537 NCT00484328

Peginterferon alfa-2b (SCH 54031)NOT in gene-target list

· 5 trials · source: ClinicalTrials.gov
NCT00723931 NCT00705666 NCT00302081

pegylated interferon alpha 2a and ribavirinNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT00540345 NCT00540345 NCT00629967

DanoprevirNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT01220947 NCT01220947 NCT01220947

daclatasvir (BMS-790052)NOT in gene-target list

Approved · 3 trials · source: ClinicalTrials.gov
NCT01051414 NCT01016912 NCT01016912

Peginterferon alfa-2a

· 3 trials · source: ClinicalTrials.gov
NCT00006164 NCT00491244 NCT01853254

ribavirin (SCH 18908)NOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT00302081 NCT00302081 NCT00705666

PegIntron (peginterferon alfa-2b; SCH 54031)NOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT00724854 NCT00081770 NCT00081770

Pegylated interferon alfa-2a and ribavirinNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00540345 NCT00629967

Ritonavir

· 2 trials · source: ClinicalTrials.gov
NCT01220947 NCT01323257

Sofosbuvir/Velpatasvir

· 2 trials · source: ClinicalTrials.gov
NCT03057847 NCT03809533

erythromycinNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01323257 NCT01323257

simeprevir (TMC435)NOT in gene-target list

Approved · 2 trials · source: ClinicalTrials.gov
NCT01323257 NCT01323257

BI 201335 NA 120 mg capsuleNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01704846 NCT01704846

BI 201335 NA 40 mg capsuleNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01704846 NCT01704846

Peginterferon alfa-2a [Pegasys]NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT01066819 NCT00475072

Rebetol (ribavirin; SCH 18908)NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00724854 NCT00081770

pegylated interferon alpha 2a, ribavirinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02377856

pegylated interferon alpha 2a and plus ribavirinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00540345

VitaliverNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00562783

Telaprevir; EscitalopramNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00933894

CP 675,206NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01008358

CopegusNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01220947

PegasysNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01220947

ABT-450/r/ABT-267, ABT-333NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01833533

asunaprevir (BMS-650032)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT01051414

Appointment + reminderNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02752152

ReminderNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02752152

No appointment and no reminderNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02752152

Peginterferon alfa-2a + RibavirinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00006164

Glecaprevir/PibrentasvirNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03235349

FK788NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00047814

Daclatasvir, Asunaprevir and BMS-791325 FDCNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02104843

beclabuvir (BMS-791325)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02104843

RosuvastatinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02104843

Peginterferon alfa-2a and ribavirinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00491244

telaprevir (VX-950)NOT in gene-target list

Approved · 1 trial · source: ClinicalTrials.gov
NCT00251199

peginterferonNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251199

DarunavirNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01323257

Pegylated-Interferon Alfa 2b (PEG-IFN)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01482767

Ribavirin (RBV)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01482767

Boceprevir (BOC)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01482767

PegIntronNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00709228

RebetolNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00709228

AutoinjectorNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01087944

Pre-filled syringeNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01087944

GS-5885 tabletNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01434498

GS-9451 tabletNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01434498

tegobuvir capsuleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01434498

ribavirin tabletNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01434498

placebo matching tegobuvir capsuleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01434498

SOF/LDV (sofosbuvir/ledipasvir)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02786537

PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02786537

EBR/GZR (elbasvir/grazoprevir)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02786537

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.